Trademark: 79378524
Word

Status
Pending
Status Code
681
Status Date
Wednesday, September 18, 2024
Serial Number
79378524
Mark Type
2
Filing Date
Friday, May 5, 2023
Published for Opposition
Tuesday, October 22, 2024

Trademark Owner History

Classifications
40 Custom manufacturing services for others in the field of peptide and olignuclotide manufacturing
5 Synthetic peptides for pharmaceutical purposes, namely, for use in oncology, metabolic disorders, neurology, gastrointestinal diseases, cardiovascular, reproductive health, immune system, nutritional disorders hormonal disorders, musculoskeletal disorders, anesthetics, cns, immunology for the treatment of obesity, diabetes, cancer, endometriosis, up-regulation of growth hormone, lipodystrophy in hiv/aids, sleeping disorders, endometriosis, autoimmune diseases, esophageal hemorrhage, hypercalcemia, dental infiltration, irritable bowel syndrome, hypotension, achondroplasia, multiple myeloma, non-metastatic osteosarcoma, erectile dysfunction, delaying imminent pre-term birth, postpartum hemorrhage, spinocerebellar degeneration, hypoactive sexual desire disorder, osteoporosis, post-menopausal osteoporosis, chronic idiopathic constipation, acute decompensated heart failure, sepsis and septic shock, acute attacks of hereditary angioedema, gastrointestinal bleeding, treatment of hiv-1, reduction of hiv lipodystrophy, severe chronic pain, chronic immune thrombocytopenic purpura, treatment of anemia associated with kidney disease, prevention of respiratory distress syndrome, prevention of phototoxicity, myocardial infarction, treatment of refractory hypotension in adults with septic or other distributive shock, irritable bowel syndrome, myasthenia gravis, uremic pruritus, renal puritus, hepatorenal syndrome, growth hormone related diseases, acromegaly, esophageal varices, bed wetting, polyuria, hyperuresis, hemophilia a, premature labor, tocolysis, autoimmune diseases, infantile spasms, rheumatoid arthritis, multiple sclerocsis, hepatitis b, treatment of chushing's disease, treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, diagnose of somatostatin receptor-positive neuroendocrine tumors, bacterial infections, viral infections, fungal infections, cardiovascular diseases, endocrine disorders, neurological conditions, allergic reactions plant; synthetic oligonucleotides for pharmaceutical purposes for use in oncology, neurology, rare diseases for the treatment of genetic disorders, neurodegenerative diseases and cancer; pharmaceutical and veterinary preparations, namely, synthetic peptides for pharmaceutical and veterinary purposes for fertility control in animals, induction of ovulation in mares, castration of dogs, facilitation of parturition in livestock; biological preparations for medical and veterinary purposes, namely, polypetide biochemicals for medical and veterinary purposes for oncology, metabolic disorders, neurology, gastrointestinal diseases, cardiovascular, reproductive health, immune system, nutritional disorders hormonal disorders, musculoskeletal disorders, anesthetics, cns, immunology for the treatment of obesity, diabetes, cancer, endometriosis, up-regulation of growth hormone, lipodystrophy in hiv/aids, sleeping disorders, endometriosis, autoimmune diseases, esophageal hemorrhage, hypercalcemia, dental infiltration, irritable bowel syndrome, hypotension, achondroplasia, multiple myeloma, non-metastatic osteosarcoma, erectile dysfunction, delaying imminent pre-term birth, postpartum hemorrhage, spinocerebellar degeneration, hypoactive sexual desire disorder, osteoporosis, post-menopausal osteoporosis, chronic idiopathic constipation, acute decompensated heart failure, sepsis and septic shock, acute attacks of hereditary angioedema, gastrointestinal bleeding, treatment of hiv-1, reduction of hiv lipodystrophy, severe chronic pain, chronic immune thrombocytopenic purpura, treatment of anemia associated with kidney disease, prevention of respiratory distress syndrome, prevention of phototoxicity, myocardial infarction, treatment of refractory hypotension in adults with septic or other distributive shock, irritable bowel syndrome, myasthenia gravis, uremic pruritus, renal puritus, hepatorenal syndrome, growth hormone related diseases, acromegaly, esophageal varices, bed wetting, polyuria, hyperuresis, hemophilia a, premature labor, tocolysis, autoimmune diseases, infantile spasms, rheumatoid arthritis, multiple sclerocsis, hepatitis b, treatment of chushing's disease, treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, diagnose of somatostatin receptor-positive neuroendocrine tumors, bacterial infections, viral infections, fungal infections, cardiovascular diseases, endocrine disorders, neurological conditions, allergic reactions plant; medicated dandruff and hair loss shampoos, medicated hair lotions for treating dandruff hair loss and hair damage, medicated soap cleansers for the skin, and medicated cosmetics, namely creams for treating acne, irritated, itching, and inflamed skin, repairing skin damage and promoting wound healing; medical being medicated hair lotion; medicated soap; sanitary preparations for medical purposes; medicated and sanitizing soaps and detergents; dietetic substances in the nature of protein dietary supplements; protein nutritional supplements; collagen dietary supplements; collagen nutritional supplements; collagen peptide dietary supplements; collagen peptide nutritional supplements adapted for medical use; food for babies; dietetic food adapted for medical use; dietetic food adapted for veterinary use; plasters for medical purposes; materials for dressings, namely, medical dressings; material for stopping teeth; dental wax; disinfectants; preparations for destroying vermin; fungicides; herbicides; vaccines
3 Non-medicated soaps; perfumery; essential oils; cosmetics; hair lotions; dentifrices
35 Advertising services; business administration; business management; providing office function
1 Biological preparations for use in industry and science; peptides for industrial purposes; oligonucleotides for industrial purposes
42 Research and development services relating to vaccines; product research and development services; research and development services in the field of peptide and oligonucleotide manufacturing
The mark consists of a stylized atomic model in green. The white in the mark is background only and is not claimed as a feature of the mark.
The color(s) green is/are claimed as a feature of the mark.

Trademark Events
Sep 19, 2023
Application Filing Receipt Mailed
Sep 14, 2023
Sn Assigned For Sect 66a Appl From Ib
Sep 15, 2023
New Application Office Supplied Data Entered
Jan 31, 2024
Assigned To Examiner
Feb 6, 2024
Non-Final Action Written
Feb 28, 2024
Refusal Processed By Mpu
Mar 19, 2024
Refusal Processed By Ib
Feb 7, 2024
Non-Final Action (Ib Refusal) Prepared For Review
Feb 28, 2024
Non-Final Action Mailed - Refusal Sent To Ib
Aug 28, 2024
Correspondence Received In Law Office
Aug 28, 2024
Teas/Email Correspondence Entered
Aug 28, 2024
Teas Response To Office Action Received
Sep 16, 2024
Examiners Amendment E-Mailed
Sep 16, 2024
Examiner's Amendment Entered
Sep 16, 2024
Examiners Amendment -Written
Sep 16, 2024
Approved For Pub - Principal Register
Sep 16, 2024
Notification Of Examiners Amendment E-Mailed

Trademark Alertz updated from USPTO on 2030-01-24